The FDA says the extensively reviewed drug should not be used for sinusitis and bronchitis but will remain approved for treating more serious pneumonia. The agency cited liver toxicity risks and said a new boxed warning for Sanofi-Aventis' Ketek would caution the drug should not be taken by patients with the muscle disorder myasthenia gravis.

Related Summaries